An investigational drug known as APT102 significantly reduced damage to heart muscle from a heart attack and minimized the risk of bleeding during follow-up treatments, according to an animal study based on a decade of work by APT Therapeutics, scientists at Washington University School of Medicine in St. Louis and colleagues at Cornell and Harvard.
Standard heart attack treatment often causes heart tissue damage. Once the blood clot that causes a heart attack is removed from an artery, molecules from dead and dying cells mix with blood rushing back through the artery. One of these molecules, adenosine triphosphate (ATP), is inflammatory; another, adenosine diphosphate (ADP), causes more clotting.
“ATP and ADP have different roles, but they both lead to more heart damage as they flood through the reopened artery after a heart attack,” said senior author Dana Abendschein, PhD, associate professor of medicine and of cell biology and physiology at Washington University.
APT102, invented and patented by APT Therapeutics, is a genetically-engineered version of the human protein apyrase, which transforms ATP and ADP into a benign molecule, adenosine monophosphate. Another enzyme changes this molecule into adenosine, which is beneficial for the heart.
“Adenosine opens the blood vessels, increases blood flow and also has a protective effect on the lining of the vessels,” said Abendschein. “It takes the bad products away and produces a good byproduct that’s protective.”
The scientists treated 21 dogs for the study. After the clots that caused their heart attacks were dissolved using medication, eight received the standard post heart-attack drug clopidogrel, a blood thinner; seven were given low doses of APT102; and six were given high doses of APT102.
The researchers found that treatment with APT102 significantly reduced the amount of irreversible heart muscle damage.
“That’s a huge benefit because the majority of patients who have a lot of heart muscle damage go on to have heart failure,” Abendschein said.
By breaking down the clotting factor ADP, treatment with APT102 also eliminated the return of the clots, which can lead to further heart damage.
“Virtually every agent that’s being used in patients now to prevent clot formation blocks the blood clotting agents known as platelets, and that creates a risk of bleeding,” Abendschein said. “This is not true of APT102.”
Other anticlotting agents have to be digested and converted into their active form in the liver, but APT102 can be injected directly into a vein, where it works immediately.
“When it comes to heart attack treatment, the saying is ‘time is muscle’ — the longer you delay treatment, the more irreversible damage the heart will suffer,” Abendschein said. “APT102 may help us save critical time by letting treatment start right away.”
The researchers hope to start clinical trials of the drug in people within the next year.
Citation: Moeckel D, Jeong SS, Sun X, Broekman MJ, Nguyen A, Drosopoulos JHF, Marcus AJ, Robson SC, Chen R, Abendschein D. Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. Science Translational Medicine, Aug. 6, 2014.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Moderate Pot Use By Adolescents Doesn't Hurt IQ
- Dopamine Receptor Agonist Drugs Linked To Gambling And Hypersexuality
- What's Hiding Under The Clouds Of Venus - Heavy Metal Frost?
- Ashes And Vegetables: The Diet Of Roman Gladiators Was Rather Poor
- New Pill-only Regimens Cure Patients With Hardest-to-treat Hepatitis C Infection
- Government Math: More Will Lose Health Insurance Than Gained It If ACA Subsidies Are Eliminated
- Manly Men And Feminine Women Are Not Evolutionary Mandates - They Are Urban Ones
- "Hey maybe it's not showing correctly on my iPad, but the link you included doesn't go directly..."
- "Our daughter had a serious adverse reaction to the MMR. When the HPV vaccine was offered we opted..."
- "Just like how the ability to learn language is ingrained, not any specific language, so certain..."
- "Since there's no actual link between vaccines and autism, I think the phrase Vaccines have been..."
- "I'll not argue that humanity made God in their image, because we sought to explain something we..."
- Should Science and Nature run advertorial by wacky Dr. Bronner’s that misleads on GMOs?
- Jack the Ripper’s identity remains a mystery after error in DNA analysis revealed
- Seed patent primer: Is the use of GMOs preventing farmers from reusing their seeds?
- History of penetrative sex reveals unexpected reversal in evolution
- Bleeding of Aloha: Ugliness of the anti-GMO movement in Hawaii
- Mutagenesis: One way Europeans wish it was 1936 again
- UCSF researchers identify key factor in transition from moderate to problem drinking
- Expert highlights research innovation and is optimistic about the future of IBS treatment
- Alternate approach to traditional CPR saves lives
- Once CD8 T cells take on one virus, they'll fight others too
- 11 million will lose health insurance if ACA subsidies are eliminated, study finds